Thymoma and Thymic Carcinoma Clinical Trial
Official title:
Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery
This is an investigational, single arm study.
Pembrolizumab is FDA approved and commercially available for treatment of many types of cancers. It is considered investigational to use chemotherapy combined with pembrolizumab to treat thymoma or Thymic carcinoma. Subjects will be evaluated for eligibility during a 28-day screening period. Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab. Response rate assessed by the site investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Up to 40 participants will be enrolled in this study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00003283 -
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
|
Phase 2 | |
| Completed |
NCT00372840 -
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
|
N/A | |
| Completed |
NCT00024076 -
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
|
Phase 2 | |
| Completed |
NCT02636556 -
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
|
N/A | |
| Completed |
NCT02049047 -
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT02633514 -
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT03663764 -
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
|
Phase 2 | |
| Recruiting |
NCT06301945 -
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
|